Brief: H Lundbeck Narrows Full-Year Guidance For Revenue

H Lundbeck A/S

08/11/2023 06:39

Nov 8 (Reuters) - H Lundbeck A/S  HLUNb.CO :
    * NARROWS ITS FULL-YEAR GUIDANCE FOR REVENUE AND NOW EXPECTS
REVENUE TO REACH DKK 19.8 TO 20.1 BILLION COMPARED TO PREVIOUSLY
DKK 19.5 TO 20.1 BILLION
    * FINANCIAL GUIDANCE FOR ADJUSTED EBITDA HAS BEEN NARROWED
AND
RAISED DUE TO LOWER THAN EXPECTED RESEARCH AND DEVELOPMENT COSTS
    * OUTLOOK: ADJUSTED EBITDA IS NOW EXPECTED TO REACH DKK 5.6
TO 5.8
BILLION COMPARED TO PREVIOUSLY DKK 5.2 TO 5.6 BILLION
    * EBIT DECLINING BY 6% (-14% CER) REFLECTING HIGHER REVENUE
COMBINED WITH INCREASED OPEX-RATIO DRIVEN BY NEGATIVE IMPACT OF
VYEPTI® PROVISION FOR OBSOLESCENCE, INCREASE IN VYEPTI®
AMORTIZATION AND HIGHER LEGAL PROVISIONS FOR ONGOING LITIGATIONS
    * MATURE BRANDS EXPECTED TO FACE STRONGER GENERIC EROSION,
ESPECIALLY ON CIPRALEX®/LEXAPRO® IN JAPAN, DEANXIT® IN CHINA AND
SABRIL® IN THE U.S
    * THE REST OF 2023 EXPECTED TO BE DAMPENED WHEN COMPARED TO
THE
FIRST HALF OF 2023 BY TIMING OF SHIPMENTS IN THE FIRST HALF OF
THE YEAR
    * MID-TERM TARGETS ARE CONFIRMED

Source text for Eikon:  ID:nWkrbQLq96 
Further company coverage:  HLUNb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))